CBS, Inc.

LOS ANGELES--( BUSINESS WIRE )--For the seventh consecutive year, iHeartMedia Los Angeles’ KOST 103.5 will join Children’s Hospital Los Angeles on Giving Tuesday, Nov. 29, for its Season of Giving fundraising campaign. Giving Tuesday, the international day of charitable giving that takes place on the first Tuesday after Thanksgiving, kicks off CHLA’s Season of Giving campaign, which runs through the end of the year and appeals to the community to donate funds that will directly support the pediatric medical care the hospital provides. Starting with The Ellen K Morning Show, KOST 103.5 will dedicate 12 hours of programming to Giving Tuesday, highlighting patient stories of hope and healing and featuring the world-class care that Children’s Hospital Los Angeles provides. Ellen K and her co-host Ryan Manno will anchor the broadcast from 6 a.m. to 6 p.m. along with fellow KOST 103.5 on-air personalities Kari Steele and Sandy Stec. Throughout the day KOST 103.5 will feature interviews with CHLA patient families, hospital leaders and long-time celebrity supporters. KOST listeners are invited to support the hospital and donate by visiting kost1035.com/CHLA or calling 1-800-909-CHLA (2452). In addition, KTLA will join the effort with anchor Megan Henderson broadcasting live from the iHeart studios to feature interviews with CHLA patient families and celebrity supporters. KTLA viewers can donate via CHLA.org/KTLA or 1-800-770-CHLA (2452). “In the past six years, more than $1.5 million has been raised on Giving Tuesday, and that is in large part due to the longstanding partnership we have with KOST,” says Children’s Hospital Los Angeles President and CEO Paul S. Viviano. “We are grateful for the support of our fellow community members and our corporate sponsors that contribute so generously and help us fulfill our mission of creating hope and building healthier futures for children." “The Giving Tuesday broadcast is a special and meaningful tradition that we look forward to all year,” says Ellen K, whose son received emergency medical care at CHLA seven years ago after suffering a football injury. “It’s an incredible privilege to see the community come together to give back year over year to this incredible institution that has made such an impact for me and my family and for millions of children around Southern California and beyond.” A generous anonymous donor, along with SchoolsFirst Federal Credit Union, the nation's largest educational credit union that has served California school employees and their families since 1934, and CBS Studios, the television production arm of the CBS network that produces such shows as NCIS, CSI and The Talk, are Giving Tuesday’s premier matching sponsors and will double every donation, dollar for dollar, for a combined total of $150,000 in matched gifts. In addition, donors will have the opportunity to make their gift go even further. For each contribution of $25 or more made before midnight Tuesday, Nov. 29, CHLA will give a My Hand In Yours fleece-lined winter beanie to a hospitalized patient. My Hand In Yours is a company founded in 2020 by actress, author and children’s health advocate Jamie Lee Curtis. 100 percent of the company’s proceeds support Children’s Hospital Los Angeles. The community can also support CHLA through these local retail experiences: More than 200 Rite Aid stores are supporting Children’s Hospital Los Angeles in November through their annual Children’s Miracle Network Hospitals campaign. Rite Aid will load $1 Bonus Cash to your Rite Aid Rewards account when you donate $1 or more at the register by Wednesday, November 30. Porto’s Bakery and Café will donate a portion of the proceeds from all cheese roll sales across six bakeries (Glendale, Burbank, Downey, Buena Park, West Covina and Northridge) from Monday, Nov. 28 to Friday, Dec. 2. Visit Sleep CoCo online at SleepCoCo.com from Tuesday, Nov. 29 – Saturday, Nov. 29 and 50% of your purchase of any Sleep Coco product will benefit CHLA. From Giving Tuesday through the end of December, Givingli – a gifting platform that allows people to customize and send digital greetings and gifts instantly--will offer a CHLA eGift, allowing users to donate to CHLA on behalf of the recipient as a gift. Visit a participating Ace Hardware through the end of December to round up your purchase and support CHLA. Stop into any 7-Eleven location now through Jan. 10 and make a donation by rounding up at checkout. Visit the Kendra Scott store at the Point in El Segundo on Saturday, Dec. 10. Donate a toy and get 20 percent off your total purchase, plus a portion of sales will be donated back to CHLA. Donations to the Season of Giving campaign through the end of the year will ensure that every patient treated at CHLA receives the critical, lifesaving care they need. Children’s Hospital Los Angeles is one of the top pediatric academic medical and research institutions in the United States and relies on the generosity of community support. iHeartMedia is the leading media outlet in the Los Angeles market with multiple platforms, including its broadcast stations; live events; data; and its digital businesses and platforms, including mobile, social and its own iHeartRadio, iHeartMedia’s free all-in-one digital music, podcasting and live streaming radio service – with more than 3 billion app downloads and more than 160 million registered. About Children's Hospital Los Angeles Children’s Hospital Los Angeles is at the forefront of pediatric medicine, offering acclaimed care to children from across the world, the country and the greater Southern California region. Founded in 1901, Children’s Hospital Los Angeles is the largest provider of care for children in Los Angeles County, the No. 1 pediatric hospital in California and the Pacific region, and is consistently ranked in the top 10 in the nation on U.S. News & World Report’s Honor Roll of Best Children’s Hospitals. Clinical expertise spans the pediatric care continuum for newborns to young adults, from everyday preventive medicine to the most medically complex cases. Inclusive, compassionate, child- and family-friendly clinical care is led by physicians who are faculty members of the Keck School of Medicine of USC. Physicians translate the new discoveries, treatments and cures proven through the work of scientists in The Saban Research Institute of Children’s Hospital Los Angeles—among the top 10 children’s hospitals for National Institutes of Health funding—to bring answers to families faster. The hospital also is home to one of the largest training programs for pediatricians in the United States. To learn more, follow us on Facebook , Instagram , LinkedIn , YouTube and Twitter , and visit our blog at CHLA.org/blog . About iHeartMedia Los Angeles iHeartMedia Los Angeles owns and operates KIIS-FM, KBIG-FM, KOST-FM, KRRL-FM, KYSR-FM, KFI-AM, KLAC-AM, KEIB-AM and is part of iHeartMedia. iHeartMedia, Inc. [Nasdaq: IHRT] is the leading audio media company in America, reaching over 90% of Americans every month. iHeart’s broadcast radio assets alone have more consumer reach in the U.S. than any other media outlet; twice the reach of the next largest broadcast radio company; and over four times the ad-enabled reach of the largest digital only audio service. iHeart is the largest podcast publisher according to Podtrac, with more downloads than the next two podcast publishers combined and has the number one social footprint among audio players, with seven times more followers than the next audio media brand, and the only fully integrated audio ad tech solution across broadcast, streaming and podcasts. The company continues to leverage its strong audience connection and unparalleled consumer reach to build new platforms, products and services. Visit iHeartMedia.com for more company information.

Cold Spring Harbor Laboratory's annual gala honors Pfizer Chairman & CEO Dr. Albert Bourla and 2020 Nobel laureate Dr. Jennifer Doudna COLD SPRING HARBOR, N.Y., Nov. 10, 2022 /PRNewswire/ -- On November 9, Cold Spring Harbor Laboratory (CSHL) held its 17th annual Double Helix Medal dinner (DHMD) at the Museum of Natural History in New York City. This year's gala honored Pfizer Chairman and CEO Dr. Albert Bourla and 2020 Nobel laureate Dr. Jennifer A. Doudna. CBS journalist Leslie Stahl returned to emcee the event, which raised a record $5.8 million for biological research. Continue Reading Left to right: CSHL President and CEO Bruce Stillman, CSHL Board of Trustees Chair Marilyn Simons, and 2022 Double Helix Medal recipients Albert Bourla and Jennifer A. Doudna. Bourla and Doudna were honored for their contributions to genetics research and public health. Image: Sean Zanni / Patrick McMullan Company Dr. Bourla spearheaded Pfizer's efforts to develop a safe and effective COVID-19 vaccine. The company delivered the first FDA-approved vaccine in only eight months. This process usually takes about eight to 10 years. Bourla is now focusing Pfizer's resources across a wide range of therapeutic areas. These include cancer, cardiovascular disease, and inflammatory conditions. "What excites me the most about Pfizer's impact on global health is the scale," Bourla says. "We are changing patients' lives. We are giving hope to people, hope for science—and that's something that gives us a lot of pride." Dr. Doudna earned the 2020 Nobel Prize in Chemistry for the development of CRISPR-Cas9. This groundbreaking tool allows scientists to precisely edit DNA. It has revolutionized human and agricultural genetics research. Following CRISPR's widespread adoption, Doudna has emerged as a leading voice on the ethical implications of gene editing. "When I think about new therapeutics that are only possible using CRISPR technology, I'm thinking about ways that we can not just treat a genetic disorder chronically, but can provide a one-and-done cure," Doudna says. "That's so transformative for patients." The 2022 DHMD was chaired by Ms. Jamie Nicholls and Mr. O. Francis Biondi, Ms. Barbara Amonson and Dr. Vincent Della Pietra, Drs. Pamela Hurst-Della Pietra and Stephen Della Pietra, Mr. and Mrs. John M. Desmarais, Ms. Elizabeth McCaul and Mr. Francis Ingrassia, Mr. and Mrs. Jeffrey E. Kelter, Dr. and Mrs. Tomislav Kundic, Mr. and Mrs. Robert D. Lindsay, Ms. Ivana Stolnik-Lourie and Dr. Robert Lourie, Dr. and Mrs. Howard L. Morgan, and Drs. Marilyn and James Simons. Since the inaugural gala in 2006, the DHMD has raised over $55 million to support CSHL's biological research and education programs. Notable past honorees include Muhammad Ali, Kareem Abdul-Jabbar, and Alan Alda. About Cold Spring Harbor Laboratory Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,000 people including 600 scientists, students, and technicians. For more information, visit SOURCE Cold Spring Harbor Laboratory

Record revenue of $40.7 million increased 21% over Q3 2021; biopreservation media revenue growth of 50%, validating leading position as a critical cell and gene therapies tool supplier Cash flow from operations of $1.5 million and adjusted EBITDA of $1.4 million Tightens 2022 revenue guidance range reflecting year-over-year growth of 34% to 38% and organic growth of 37% to 40% Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Nov. 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the three and nine months ended September 30, 2022. Mike Rice, Chairman and CEO, commented, "Against a backdrop of several macro headwinds affecting the life science tools industry, our team delivered a strong quarterly performance from our diversified offering of products and services, setting the stage for record full-year revenue. We are tightening our 2022 revenue guidance range and have a bullish outlook for 2023, driven by strong growth expectations from our Cell Processing platform." "Our high-margin biopreservation media product line, which is recurring consumables revenue, grew 50% over Q3 2021. With our year-to-date results, BioLife has validated its position as a CGT tools leader. We generated record total revenue for Q3 despite a prior year comparable that included significant COVID-related revenue. We continue to diversify our customer base and increase cross-selling success by partnering with customers to drive adoption of multiple platforms, all of which can reduce risk in CGT manufacturing, storage and distribution. It's important to note that in Q3, 44% of total revenue was from proprietary consumables and 18% was from recurring service revenue, so over 60% of total revenue was from non-capital equipment sales." Troy Wichterman, CFO, added, "We achieved positive adjusted EBITDA of $1.4 million for the third quarter, with further gains expected in Q4 2022. Although we continue to experience strong demand for our biopreservation media products, we are adjusting the top of our 2022 revenue guidance range to reflect expected shipment delays related to industry-wide supply-chain challenges impacting our cryogenic freezer product line. Any delays are expected to create a backlog of orders that we expect to ship in Q1 2023." Operational Highlights For the third quarter of 2022, we gained 193 new direct customer sites including 14 for biopreservation media, 11 for ThawSTAR® systems, 12 for evo® cold chain management services, 14 for CBS cryogenic freezers and accessories, 114 for Stirling ULT freezers and accessories, 18 for SciSafe® biologic storage services and 10 for Sexton cell processing products. For the third quarter of 2022, we received 19 new U.S. FDA Drug Master File cross-reference requests, indicating the planned use of CryoStor® or HypoThermosol® in pending CGT clinical trials. To date, we estimate our biopreservation media products have been used in or are planned to be used in 570 customer clinical applications, including 11 approved CGT products and at least 10 therapies with regulatory filings expected to be submitted in 2022 or 2023. We continue to estimate annual biopreservation media revenue per approved commercial application will range from $500,000 to $2 million. Use of our evo cold chain solution by CGT end customers continued to increase in Q3 2022. Our more than 2,000 courier partner shipments were up 100% over Q3 2021. This adoption validates our belief that the evo platform will increasingly be selected as a class-defining temperature-controlled shipping container and related cloud app by leading CGT companies. We are currently supporting four of the six currently approved CAR T-cell therapies. By mid 2023, we expect the evo platform to be used in all of the currently approved CAR T-cell therapies. Biological storage services revenue increased significantly in Q3 2022 as we onboarded 18 new customers. Due to increased interest from several global pharma companies and healthcare organizations, we are evaluating several potential sites for our next biorepository location. We expect to finalize a decision in early 2023. ULT freezer quality continued to improve in Q3 2022 and product lead times were reduced from 12 weeks to zero since the beginning of 2022, despite continued supply chain disruptions. Our field upgrade is about 70% complete and we expect to materially conclude upgrades by the end of the year. Our sales team and distributors continue to drive ULT freezer sales to non-COVID-19 customers, including CGT developers. Third Quarter 2022 Financial Results BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted Accounting Principles (GAAP) and as adjusted (non-GAAP). A reconciliation of GAAP to non-GAAP metrics appears at the end of this news release. REVENUE Total revenue for the third quarter of 2022 was $40.7 million, an increase of $6.9 million, or 21%, from $33.8 million for the third quarter of 2021. Organic revenue growth was 18%. COVID-19 related revenue was approximately 9%, compared with approximately 18% in Q3 2021. Cell Processing platform revenue was $18.1 million, up $6.6 million, or 57%, over the same period in 2021. Biopreservation media and organic cell processing growth were both 50%. Freezers and Thaw Systems platform revenue was $15.3 million, down $2.3 million, or (13%), over the same period in 2021, due to a decline in COVID-related revenue which was 23% of platform revenue in Q3 2021 versus only 4% of platform revenue in Q3 2022. This platform was impacted by supply-chain issues that delayed the shipment of several cryogenic freezer orders, which have already shipped or will ship in Q4. Storage and Storage Services platform revenue was $7.3 million, up $2.6 million, or 56%, over the same period in 2021. Organic growth was 56%. COVID-19 related revenue was approximately 40% for this platform. Total revenue for the first nine months of 2022 was $117.5 million, an increase of $35.6 million, or 44%, from $81.9 million for the first nine months of 2021. Organic revenue growth was 44%. COVID-19 related revenue was approximately 9%, compared with approximately 16% in 2021. Cell Processing platform revenue was $48.3 million, up $18.2 million, or 60%, over 2021. Organic growth was 49%. Freezers and Thaw Systems platform revenue was $49.3 million, up $9.3 million, or 23%, over 2021. Organic growth was 10%. COVID-19 related revenue was approximately 4%. Storage and Storage Services platform revenue was $19.8 million, up $8.1 million, or 69%, for the total and organic growth over 2021. COVID-19 related revenue was approximately 45%. GROSS MARGIN Gross margin (GAAP) for the third quarter of 2022 was 31% compared with 25% for the third quarter of 2021. Adjusted gross margin (non-GAAP) for the third quarter of 2022 was 34% compared with 28% for the third quarter of 2021. Gross margin (GAAP) for the first nine months of 2022 was 31% compared with 36% for the first nine months of 2021. Adjusted gross margin (non-GAAP) for the first nine months of 2022 was 34% compared with 39% for the first nine months of 2021. The change in gross margin in both periods was primarily due to a shift in product mix after the acquisition of Global Cooling, Inc. (Stirling Ultracold), which has lower gross margins than the remainder of BioLife's portfolio. The sequential quarterly decline in GAAP and non-GAAP gross margin was primarily due to supplier quality issues impacting yield and customer mix. OPERATING EXPENSE Operating expense (GAAP) for the third quarter of 2022 was $52.2 million compared with $45.0 million for the third quarter of 2021. Adjusted operating expense (non-GAAP) for the third quarter of 2022 was $20.5 million compared with $17.4 million for the third quarter 2021. Operating expense (GAAP) for the first nine months of 2022 was $212.8 million compared with $98.5 million for the first nine months of 2021. Adjusted operating expense (non-GAAP) for the first nine months of 2022 was $60.3 million compared with $39.5 million for the first nine months of 2021. The increase in GAAP operating expense for the first nine months of 2022 was primarily due to a non-cash impairment charge of $69.9 million related to the acquired intangible assets of Global Cooling, Inc. (Stirling Ultracold). Adjusted operating expenses (non-GAAP) increased due to the full period of ownership from the acquisition of Global Cooling, Inc. on May 3, 2021, and the acquisition of Sexton Biotechnologies, Inc. on September 1, 2021. In addition, operating expenses increased due to higher accounting costs related to becoming a Large Accelerated Filer and additional headcount to support our growth. OPERATING INCOME/(LOSS) Operating loss (GAAP) for the third quarter of 2022 was $11.4 million compared with operating loss of $11.2 million for the third quarter of 2021. Adjusted operating loss (non-GAAP) for the third quarter of 2022 was $6.7 million compared with $8.1 million for the third quarter of 2021. Operating loss (GAAP) for the first nine months of 2022 was $95.3 million compared with operating loss of $16.7 million for the first nine months of 2021. Adjusted operating loss (non-GAAP) for the first nine months of 2022 was $20.2 million compared with $7.5 million for the first nine months of 2021. NET INCOME/(LOSS) Net loss (GAAP) for the third quarter of 2022 was $10.0 million compared with net income of $79,000 for the third quarter of 2021. Adjusted net loss (non-GAAP) for the third quarter of 2022 was $6.6 million compared with adjusted net loss of $8.3 million for the third quarter of 2021. Net loss (GAAP) for the first nine months of 2022 was $89.6 million compared with net income of $6.8 million for the first nine months of 2021. Adjusted net loss (non-GAAP) for the first nine months of 2022 was $20.1 million compared with adjusted net loss of $7.8 million for the first nine months of 2021. EARNINGS/(LOSS) PER SHARE Loss per share (GAAP) for the third quarter of 2022 was $0.23 compared with earnings per diluted share of $0.00 for the third quarter of 2021. Loss per share (GAAP) for the first nine months of 2022 was $2.11 and included a non-cash intangible impairment charge of $1.65 per share. This compared with earnings per diluted share for the first nine months of 2021 of $0.17. ADJUSTED EBITDA Adjusted EBITDA, a non-GAAP measure, for the third quarter of 2022 was $1.4 million compared with negative $2.1 million for the third quarter of 2021. Adjusted EBITDA, a non-GAAP measure, for the first nine months of 2022 was $2.8 million compared with $4.4 million for the first nine months of 2021. CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES Cash, cash equivalents, and marketable securities as of September 30, 2022 were $62.1 million compared to $46.6 million as of June 30, 2022. The increase of cash in the third quarter was primarily related to borrowing $20 million upon closure of a term loan agreement and positive cash flow from operations of $1.5 million, offset by the repayment of a separate term loan and capital expenditures. 2022 Revenue Guidance Management is updating 2022 revenue guidance. Total revenue for 2022 is now expected to range from $160 million to $164 million compared with prior guidance of $160 million to $166 million, and reflects year-over-year growth of 34% to 38% and organic growth of 37% to 40%. COVID-19 related revenue is expected to account for approximately 7% to 8% of total revenue. This revised revenue guidance includes the following platform contributions: Cell Processing platform: $67.0 million to $68.0 million, an increase of 49% to 51% over 2021 and organic growth of 42% to 43%. This includes biopreservation media and Sexton products. Previous revenue guidance was in a range from $67.0 million to $69.5 million. This modest reduction in the top of the range is due to anticipated supply chain constraints. Freezers and Thaw Systems platform: $66.0 million to $68.0 million, an increase of 17% to 20% over 2021 and organic growth of 8% to 13%. COVID-19 related revenue is expected to account for 3% of the freezer and thaw systems platform revenue in 2022. This includes ThawSTAR thawing devices, cryogenic liquid nitrogen freezers and ULT Stirling freezers. There continues to be some supply chain risk which could impact this platform in Q1. Previous revenue guidance was in a range from $70.0 million to $71.5 million. This reduction is due to anticipated supply chain constraints. Storage and Storage Services platform: $27.0 million to $28.0 million, a total and organic increase of 54% to 59% over 2021. COVID-19 related revenue is expected to account for approximately 40% to 45% of the storage and storage services platform revenue. COVID-19 related storage revenue is primarily generated from contracts, including some that extend beyond 2022. Previous revenue guidance was in a range from $23.0 million to $25.0 million. The increase is due to anticipated increased demand for our Storage and Storage Services Although the Company does not provide guidance below the revenue line, BioLife expects positive full year adjusted EBITDA. Conference Call & Webcast Management will discuss the Company's financial results, provide a general business update and answer questions during a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT). To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at . In addition, the conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers or (646) 307-1963 for international callers. The conference ID number is 8988696. A webcast replay will be available approximately two hours after the call ends and will be archived on for 90 days. About BioLife Solutions BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets. Our tools portfolio includes our proprietary CryoStor® and HypoThermosol® biopreservation media for shipping and storage, the ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, high capacity cryogenic storage freezers, Stirling Ultracold mechanical freezers, SciSafe biologic storage services, and Sexton Biotechnologies cell processing tools. For more information, please visit , , , or and follow BioLife on Twitter. Cautions Regarding Forward Looking Statements Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the Company following the completion of its 2019, 2020 and 2021 acquisitions and giving effect to the COVID-19 pandemic, the Company's ability to implement its business strategy and anticipated business and operations, in particular following its recent acquisitions and the construction and validation of a center of excellence biorepository, the expected synergies between the Company and the companies and products that it has recently acquired, the Company's ability to realize all or any of the anticipated benefits associated with its recent acquisitions, the Company's ability to address and resolve ULT freezer issues, the potential utility of and market for the Company's products and services, including the adoption of evo cold chain services by all six currently approved CAR T-cell therapies, and the Company's ability to cross sell its products and services, guidance for financial results for 2022, including regarding revenue of its recently acquired products, and potential revenue growth and changes in gross margin, adjusted gross margin and adjusted EBITDA margin, and potential market expansion, including with consideration to our recent acquisitions and giving effect to the COVID-19 pandemic, the Company's anticipated future growth strategy, including the acquisition of synergistic cell and gene therapy manufacturing tools and services or technologies, regulatory approvals and/or commercial manufacturing of our customers' products, and potential customer revenue. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, unexpected costs, charges or expenses resulting from our recent acquisitions, market adoption of the Company's products (including the Company's recently acquired products), the ability of our recent acquisitions to be accretive on the Company's financial results, the ability of the Company to continue to implement its business strategy, uncertainty regarding third-party market projections, market volatility, competition, litigation, the impact of the COVID-19 pandemic and supply chain issues, and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law. Non-GAAP Measures of Financial Performance: To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: adjusted gross profit and gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. When analyzing the Company's operating results, investors should not consider non-GAAP measures as substitutes for the comparable financial measures prepared in accordance with GAAP. Media & Investor Relations At the Company Troy Wichterman Chief Financial Officer (425) 402-1400 [email protected] Investors LHA Investor Relations Jody Cain (310) 691-7100 [email protected] SOURCE BioLife Solutions, Inc.